Elevara Medicines has appointed Dr Mai-Britt Zocca as CEO, effective 1 July 2026. She succeeds founder Emma Tinsley, who will remain on the Board as a Non-Executive Director.
Emma Tinsley, outgoing CEO, said: “Mai-Britt is an exceptional biotechnology leader.”
She continued: “She combines deep scientific understanding with extensive operational and public company experience, and has successfully built organisations through exactly the stage Elevara is now entering.”
Mai-Britt previously founded and led IO Biotech, advancing its pipeline from phase 1 through multiple phase 2 trials and into a pivotal global phase 3 study. She also founded a biotechnology venture focused on repurposing small molecules for cancer and neurodegenerative diseases.
Her earlier roles include senior leadership positions at Danish Biotech and Danish Chamber of Commerce, as well as posts supporting innovation and life science start-ups. She holds an MSc in Biochemistry and a PhD in Medicine from the University of Copenhagen and National Cancer Institute, NIH.
Mai-Britt said: “What attracted me to Elevara was not only the differentiated science behind ELV001, but also the outstanding work that Emma and the team have already accomplished.”
She added: “The confidence demonstrated by the company’s experienced investor base further strengthened my conviction that ELV001 represents a unique opportunity.”
